Company news

BioArctic AB news in 2026

BioArctic AB's news releases, calls and decks from 2026, newest first.

View company

BioArctic publishes the Annual Report and Sustainability Report for 2025

April 21, 2026

The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB

March 27, 2026

Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress

March 11, 2026

Number of shares and votes in BioArctic AB (publ) as of February 27, 2026

February 27, 2026

Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET

February 11, 2026

BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China

February 9, 2026

Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025

February 6, 2026

Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA

January 25, 2026

BLA for subcutaneous formulation of Leqembi® accepted in China

January 6, 2026

Calls in 2026

Decks in 2026